Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Bristol-Myers Squibb: Why I Believe Its Dominance in Cancer Immunotherapy Promises to Make BMY a Great Long-Term Investment (BMY, $62.70, Buy)

Investment Opinion

Conceptual Reason for Recommendation

My recommendation of Bristol-Myers Squibb is in contrast to the small, not well-researched biotechnology companies on…
Read more…